U.S. Colorectal Cancer Markets - Patient Outlook

SUMMARY

Research Overview

This Frost & Sullivan research service entitled the U.S. Colorectal Cancer Markets: Patient Outlook is an update to Frost & Sullivan's coverage of colorectal cancer.

Market Overview

Colorectal cancer is the third leading cancer in the United States, and is a combined designation for cancers of the colon and rectum. Treatment is complex, with new product advances in both cytotoxic and targeted therapy drugs changing the landscape of options and pathways utilized by physicians to fight the disease. With any cancer, patients are divided due to factors such as disease progression and line of chemotherapeutic therapy. Proper understanding of the potential scope of these relative patient groups in the future is important in order to judge the appropriate market size available to oncology products targeting colorectal cancer.

This research service forecasts patient growth for colon and rectal cancer by stage. Additionally, patient forecasts are provided for adjuvant therapy, first-line therapy, and second/third-line therapy. Overall trends in forecasted population growth and incidence trends are discussed, as well as defined staging for disease progression.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

Executive Summary

• 1. Introduction

Colorectal Cancer Market Update Information

• 1. Overview

2. PATIENT FORECASTS AND STAGING

Forecasts

• 1. Incidence and Staging Forecasts
• 2. Patient Forecasts by Line of Therapy

3. APPENDIX

Decision Support Databases

• 1. Red Meat Consumption
• 2. Colorectal Cancer Mortality
• 3. Smoker Prevalence
• 4. Pharmaceutical R&D Expenditure
• 5. Government R&D Expenditure in Biotechnology